Scarring Alopecia Under Immune Checkpoint Blockade: a Report of Three Cases

Authors

  • Sonja Braasch University Hospital Muenster, Department of Dermatology
  • Carsten Weishaupt University Hospital Münster, Department of Dermatology
  • Eva Spukti University Hospital Münster, Department of Dermatology
  • Markus Böhm University Hospital Münster, Department of Dermatology
  • Stephan Alexander Braun Department of Dermatology, University Hospital Münster, Von-Esmarch-Str. 58, DE-48149 Münster, Germany

DOI:

https://doi.org/10.2340/actadv.v102.2311

Keywords:

alopecia, CTLA-4, immune-related adverse event, PD-1

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12-25.

https://doi.org/10.1016/j.ejca.2016.02.010

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 22372: 320-330.

https://doi.org/10.1056/NEJMoa1412082

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-2532.

https://doi.org/10.1056/NEJMoa1503093

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.

https://doi.org/10.1056/NEJMoa1200690

Lakhmiri M, Cavelier-Balloy B, Lacoste C, Cassius C, Baroudjian B, Delyon J, et al. Nivolumab-induced alopecia areata: a reversible factor of good prognosis? JAAD Case Rep 2018; 4: 761-765.

https://doi.org/10.1016/j.jdcr.2018.05.022

Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ, et al. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 2017; 176: 1649-1652.

https://doi.org/10.1111/bjd.15237

Cogen AL, Parekh V, Gangadhar T, Lipoff JB. Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma. JAAD Case Rep 2018; 4: 132-134.

https://doi.org/10.1016/j.jdcr.2017.12.002

Bolduc C, Sperling LC, Shapiro J. Primary cicatricial alopecia. J Am Acad Dermatol 2016; 75: 1081-1099.

https://doi.org/10.1016/j.jaad.2014.09.058

Ho A, Shapiro J. Medical therapy for frontal fibrosing alopecia: a review and clinical approach. J Am Acad Dermatol 2019; 81: 568-580.

https://doi.org/10.1016/j.jaad.2019.03.079

Bertolini M, McElwee K, Gilhar A, Bulfone-Paus S, Paus R. Hair follicle immune privilege and its collapse in alopecia areata. Exp Dermatol 2020; 29: 703-725.

https://doi.org/10.1111/exd.14155

Downloads

Published

2022-10-11

How to Cite

Braasch, S., Weishaupt, C., Spukti, E., Böhm, M., & Braun, S. A. (2022). Scarring Alopecia Under Immune Checkpoint Blockade: a Report of Three Cases. Acta Dermato-Venereologica, 102, adv00792. https://doi.org/10.2340/actadv.v102.2311